Celldex Therapeutics Statistics Share Statistics Celldex Therapeutics has 66.41M
shares outstanding. The number of shares has increased by 0.09%
in one year.
Shares Outstanding 66.41M Shares Change (YoY) 0.09% Shares Change (QoQ) 0.02% Owned by Institutions (%) 99.99% Shares Floating 64.52M Failed to Deliver (FTD) Shares 1 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 6.58M, so 9.91% of the outstanding
shares have been sold short.
Short Interest 6.58M Short % of Shares Out 9.91% Short % of Float 11.71% Short Ratio (days to cover) 4.44
Valuation Ratios The PE ratio is -10.31 and the forward
PE ratio is -6.23.
Celldex Therapeutics's PEG ratio is
0.64.
PE Ratio -10.31 Forward PE -6.23 PS Ratio 231.8 Forward PS 626.4 PB Ratio 2.18 P/FCF Ratio -10.19 PEG Ratio 0.64
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Celldex Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 18.91,
with a Debt / Equity ratio of 0.01.
Current Ratio 18.91 Quick Ratio 18.91 Debt / Equity 0.01 Debt / EBITDA -0.02 Debt / FCF -0.02 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $37.74K Profits Per Employee $-848.73K Employee Count 186 Asset Turnover 0.01 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -13.83% in the
last 52 weeks. The beta is 1.33, so Celldex Therapeutics's
price volatility has been higher than the market average.
Beta 1.33 52-Week Price Change -13.83% 50-Day Moving Average 23.58 200-Day Moving Average 21.93 Relative Strength Index (RSI) 60.74 Average Volume (20 Days) 1,223,433
Income Statement In the last 12 months, Celldex Therapeutics had revenue of 7.02M
and earned -157.86M
in profits. Earnings per share was -2.45.
Revenue 7.02M Gross Profit 7.02M Operating Income -195.08M Net Income -157.86M EBITDA -191.9M EBIT -195.08M Earnings Per Share (EPS) -2.45
Full Income Statement Balance Sheet The company has 28.36M in cash and 3.81M in
debt, giving a net cash position of 24.54M.
Cash & Cash Equivalents 28.36M Total Debt 3.81M Net Cash 24.54M Retained Earnings -1.56B Total Assets 692.41M Working Capital 615.44M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -157.78M
and capital expenditures -1.92M, giving a free cash flow of -159.7M.
Operating Cash Flow -157.78M Capital Expenditures -1.92M Free Cash Flow -159.7M FCF Per Share -2.48
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -2778.89% and -2248.76%.
Gross Margin 100% Operating Margin -2778.89% Pretax Margin -2248.76% Profit Margin -2248.76% EBITDA Margin -2733.63% EBIT Margin -2778.89% FCF Margin -2274.89%
Dividends & Yields CLDX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for CLDX is $42.5,
which is 60.9% higher than the current price. The consensus rating is "Buy".
Price Target $42.5 Price Target Difference 60.9% Analyst Consensus Buy Analyst Count 8
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Feb 11, 2019. It was a
backward
split with a ratio of 1:15.
Last Split Date Feb 11, 2019 Split Type backward Split Ratio 1:15
Scores Altman Z-Score 23.78 Piotroski F-Score 2
